The changing role for extended resections in an era of advanced radiotherapy techniques and novel therapies in gynaecological malignancy
- Author(s)
- McBain, RD; McGauran, MFG; Tran, KH; Au-Yeung, G; Khaw, PYL; McNally, OM;
- Details
- Publication Year 2022-11,Volume 48,Issue #11,Page 2308-2314
- Journal Title
- European Journal of Surgical Oncology
- Publication Type
- Review
- Abstract
- Pelvic exenteration, first described in 1948 and subsequently refined, may be offered as a last hope of cure to patients with recurrent or locally advanced pelvic tumours, where radiotherapy is not an option. It is a complex, morbid, ultra-radical procedure involving en-bloc resection of the female reproductive organs, lower urinary tract, and a portion of the rectosigmoid. This article discusses the evolution of and current indications for pelvic exenteration in gynaecologic oncology as well as the reasons for its decline: primary and secondary prevention of cervical cancer (the recurrence of which is the most common indication for exenteration); improvements in treatment of cervical, endometrial, vaginal and vulvar cancer in the primary and recurrent setting; and the advent of novel therapies.
- Keywords
- Humans; Female; *Genital Neoplasms, Female/radiotherapy/surgery; *Pelvic Exenteration; *Uterine Cervical Neoplasms/radiotherapy/surgery; *Vulvar Neoplasms/radiotherapy/surgery; *Radiation Oncology; Neoplasm Recurrence, Local/prevention & control; Retrospective Studies; Cervical cancer; Endometrial cancer; Pelvic exenteration; Previously irradiated field; Recurrent gynaecologic malignancy; Vaginal cancer; Vulvar cancer
- Department(s)
- Surgical Oncology; Cancer Imaging; Medical Oncology; Radiation Oncology
- PubMed ID
- 36184421
- Publisher's Version
- https://doi.org/10.1016/j.ejso.2022.09.010
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-01-31 05:10:54
Last Modified: 2025-01-31 05:11:49